Terry Sivesind

Renovar, Inc. develops and provides diagnostic tests for kidney disease and transplant monitoring based on protein biomarkers. The company was founded by Stuart J. Knechtle and Terry Sivesind in 1999 and is headquartered in Little Chute, WI.

Wisconsin Investment Partners LLC (Wisconsin Investment Partners) is a venture capital firm founded in 2000 by Dick Leazer and Terry Sivesind. The firm is headquartered in Madison, Wisconsin.

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.

Roche Madison, Inc. provides gene transfer technologies to the pharmaceutical industry. The company was founded in 1995 by Jon Wolff, James Hagstrom and Vladimir Budker and is headquartered in Madison, WI.

Metabiologics, Inc. manufactures serotypes of botulinum toxin. The company was founded by Mike Goodnough, Carl Malizio and Terry Sivesind and is headquartered in Madison, WI.